GleamWall
中文EN

IMNN Imunon, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 749647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-4.9%
TTM EPS YoY60.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-448.6%
ROA-143.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets78.2%
Debt / equity0.00x
Current ratio1.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.79M$1.46M$2.34M$2.49M$1.90M$1.23M$2.17M$2.23M
SG&A expense$1.66M$1.33M$1.97M$1.77M$1.58M$1.54M$1.98M$1.91M
Operating income-$3.45M-$2.79M-$4.31M-$4.26M-$3.48M-$2.77M-$4.15M-$4.15M
Interest expense$264,133$77,273——————
Net income-$3.75M-$2.81M-$4.25M-$4.22M-$3.43M-$2.74M-$4.10M-$4.06M
EBITDA-$3.38M-$2.72M-$4.24M-$4.19M-$3.40M-$2.69M-$4.08M-$4.11M
EPS (basic)-0.64-0.54-0.84—-1.16-2.15-3.15—
EPS (diluted)-0.64-0.54-0.84—-1.16-2.15-3.15—
Weighted avg. shares (diluted)5.95M5.23M5.03M—2.94M1.28M1.30M—
Balance sheet
Cash & equivalents$4.04M$6.86M$4.79M$8.78M$5.25M$4.73M$2.87M$5.87M
Current assets$5.84M$8.69M$6.62M$10.72M$7.26M$6.89M$5.09M$8.01M
PP&E, net$393,696$459,016$459,936$529,936$601,425$676,565$734,243$541,272
Total assets$12.01M$14.99M$8.02M$12.29M$8.99M$8.79M$6.86M$9.72M
Current liabilities$4.24M$4.78M$4.17M$4.62M$4.20M$5.32M$5.80M$4.79M
Total liabilities$9.39M$10.80M$4.66M$5.23M$4.91M$6.13M$6.41M$5.47M
Shareholders' equity$2.62M$4.19M$3.36M$7.06M$4.08M$2.66M$452,028$4.24M
Shares outstanding6.21M4.67M3.92M3.42M2.90M1.72M14.62M966,712
Cash flow statement
Operating cash flow-$3.20M-$3.03M-$3.99M-$3.66M-$4.44M-$2.95M-$2.85M-$4.42M
Capital expenditure$1,792——$3,589$0$17,331$259,652$14,907
Free cash flow-$3.20M——-$3.66M-$4.44M-$2.97M-$3.11M-$4.44M
Investing cash flow-$1,792——-$3,589$0-$17,331-$259,652-$14,907
Financing cash flow$419,249$10.16M-$1,813$7.19M$4.96M$4.83M$105,692-$3,277
Depreciation & amortization$67,112$70,000$70,000$75,078$75,140$75,009$66,681$37,062
Stock-based compensation$90,367$93,281$548,590$11,479-$211,279$122,641$204,533$113,079

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.